与Rybrevant相关的皮肤不良事件基于FDA不良事件报告系统 (FAERS) 数据库从2021年到2024年
Yuqin Zeng1,2, Yidan Li1, Ziye Du1,2
1Department of Dermatology, Third Xiangya Hospital, Central South Universi, Changsha, Hunan, 410013, P.R. China.
Naunyn-Schmiedeberg's archives of pharmacology
|March 6, 2026
概括
瑞布雷万特 (amivantamab) 的使用与严重的皮肤问题有关,如乳和形皮肤炎. 早期监测和管理对于经历这些不良事件的患者至关重要.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 皮肤病学 皮肤病学
背景情况:
- 瑞布雷万特 (amivantamab) 是一种针对EGFR和MET的新型双特异抗体.
- 了解其现实世界的安全概况,特别是皮肤不良事件 (AE),至关重要.
研究的目的:
- 系统地评估与Rybrevant相关的皮肤AE的频谱和特征.
- 使用现实数据识别高风险事件和患者群体.
主要方法:
- 从2021年第二季度到2024年第四季度对FDA不良事件报告系统 (FAERS) 数据的分析.
- 包括1372个独特的Rybrevant病例,在首选术语 (PT) 层面分析了483个皮肤AE.
主要成果:
- 乳头炎,形皮肤炎和皮肤毒性表现出最高的信号强度.
- 毛囊炎在男性中更为常见. 皮肤AE的中位数发病时间为11天.
- 皮疹发生的时间最早 (中位数TTO<1天),皮肤毒性发生的时间最晚 (中位数139天). 住院是常见的结果.
结论:
- 与Rybrevant相关的皮肤副作用在临床实践中很常见和多样化.
- 帕罗尼基亚和形皮肤炎是需要注意的关键风险.
- 积极的监测和个性化的管理策略对于Rybrevant用户至关重要.
相关概念视频
Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Therapeutic Drug Monitoring: Affecting Factors
300
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
300
Drug Toxicity: Allergic Reactions
80
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
80
Allergic Drug Reactions
1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Skin Cancer
6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K
FDA Approved Drugs: Changes to Approved Drugs
301
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
301
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
